布地奈德、硫酸特布他林、异丙托溴铵气雾剂三联气泵雾化吸入治疗小儿喘息性支气管炎疗效观察

The Effects of Triple Inhalation Therapy of Budesonide,Terbutaline Sulphate and Ipratropium Bromide in Children with Asthmatic Bronchitis

目的:观察布地奈德、硫酸特布他林、异丙托溴铵气雾剂联合雾化吸入治疗喘息性支气管炎的临床疗效。方法:将122例喘息性支气管炎患儿随机分为治疗组62例、对照组60例,两组采用相同的抗感染、止咳、平喘等综合治疗。治疗组加用布地奈德、硫酸特布他林、异丙托溴铵气雾剂雾化吸入,体重小于10 kg者,予布地奈德1 mL、硫酸特布他林0.5 mL、异丙托溴铵气雾剂0.25 mL;体重大于10 kg者予布地奈德1 mL、硫酸特布他林1 mL、异丙托溴铵气雾剂0.5 mL,均加生理盐水2 mL混合后放雾化器中经压力雾化泵吸入,每次至药液雾化完为止,依病情2～3次/d。对照组给予α-糜蛋白酶、地塞米松雾化吸入。对治疗后症状、体征持续时间进行比较。结果:治疗组临床症状、肺部啰音消失时间均短于对照组(P<0.01)。治疗组总有效率为95.6%,对照组总有效率为75.0%,两组比较差异有统计学意义(P<0.01)。结论:布地奈德、硫酸特布他林、异丙托溴铵气雾剂联合雾化吸入治疗喘息性支气管炎可以缩短病程,提高治愈率,疗效显著,不良反应少。

Objective ：To observe the effects of triple inhalation therapy of budesonide, terbutaline sulphate and ipratropium bromide in children with asthmatic bronchitis. Methods： Randomly 122 cases of asthmatic bronchitis were divided into a treatment group of 62 patients, and a control group of 60 patients. Treatment group was treated with budesonide, terbutaline sulphate and ipratropium bromide inhalation. Patients weighing less than 10 kg received Pulmicort 1 mL, Bricanyl 0.5 mL, and Atrovent 0.25 mL 2 to 3 times daily; while those weighting greater than 10 kg received Pulmicort 1 mL, Bricanyl 1 mL, and Atrovent 0.5 mL 2 to 3 times daily. In each inhalation 2 mL of normal saline was mixed into aerosol pump. Symptoms and signs before and after treatment, and the course of disease were compared. Results： The clinical symptoms disappearance time and pulmonary rales disappearance time of the treatment group were shorter than those of the control group （P〈0.01）. The treatment group＇s total effective rate was 95.6% as opposed to the control group （with a total effective rate of 75.0% ） ; the difference was statistically significant （P〈0.01）. Conclusions： Budesonide, terbutaline sulphate and ipratropium bromide combined inhalation therapy can shorten the course of asthmatic bronchitis, increase the cure rate, and decrease adverse reactions.